Sharps Regains Nasdaq Listing Compliance
Sharps Regains Nasdaq Listing Compliance
NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market ("Nasdaq") that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024.
紐約,2024年11月18日(GLOBE NEWSWIRE)——提供一流專利注射器產品的創新醫療器械和藥品包裝公司夏普斯科技公司(納斯達克股票代碼:「STSS」 和 「STSSW」)(「夏普斯」)今天宣佈,2024年11月13日,納斯達克股票市場(「納斯達克」)通知公司,該公司已恢復遵守最低出價標準根據2024年11月5日納斯達克上市規則5550(a)(2)的規定,繼續在納斯達克股票市場上市的價格要求爲每股1.00美元。
The Company's Chief Executive Officer Robert Hayes stated, "We are extremely pleased with our bid price compliance. We view our listing on Nasdaq to be extremely important to us as a Company as it offers the Company and its shareholders the best opportunity for the future. Further, we want to thank the shareholders for their support of the reverse split that supported Sharps regaining compliance."
該公司首席執行官羅伯特·海斯表示:「我們對投標價格的合規性感到非常滿意。我們認爲,我們在納斯達克的上市對我們作爲一家公司來說極爲重要,因爲它爲公司及其股東提供了未來的最佳機會。此外,我們要感謝股東對反向拆分的支持,這支持夏普斯恢復合規。」
About Sharps Technology:
關於夏普科技:
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For additional information, please visit .
Sharps Technology 是一家創新的醫療器械和藥品包裝公司,爲醫療保健行業提供專利、一流的智能安全注射器產品。該公司的產品線側重於提供超低浪費能力,其中採用了同時使用被動和主動安全功能的注射器技術。夏普斯還提供採用專業共聚物技術設計的產品,以支持預充式注射器細分市場。該公司在匈牙利設有製造工廠,並已與Nephron Pharmicals合作擴大其在美國的製造能力。欲了解更多信息,請訪問。
Forward-Looking Statements:
前瞻性陳述:
This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," "poised" or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
本新聞稿包含 「前瞻性陳述」。前瞻性陳述反映了我們目前對未來事件的看法。在本新聞稿中使用這些術語中的 「預期」、「相信」、「估計」、「預期」、「未來」、「打算」、「計劃」、「準備就緒」 或否定詞語以及與我們或我們的管理層相關的類似表述均表示前瞻性陳述。此類聲明包括但不限於本新聞稿中與我們的業務戰略、未來經營業績和流動性以及資本資源展望有關的聲明。前瞻性陳述基於我們當前對業務、經濟和其他未來狀況的預期和假設。由於前瞻性陳述與未來有關,因此它們會受到固有的不確定性、風險和難以預測的情況變化的影響。我們的實際業績可能與前瞻性陳述所設想的結果存在重大差異。它們既不是歷史事實的陳述,也不是保證未來業績的保證。因此,我們提醒您不要依賴任何前瞻性陳述。可能導致實際業績與前瞻性陳述存在重大差異的重要因素包括但不限於我們籌集資金爲持續經營提供資金的能力;我們保護知識產權的能力;對我們提起的任何侵權訴訟或其他訴訟的影響;來自其他提供商和產品的競爭;我們開發和商業化產品和服務的能力;政府監管的變化;我們完成籌資交易的能力;以及與之相關的其他因素我們的行業、我們的運營和經營業績。實際結果可能與預期、相信、估計、預期、預期或計劃中的結果有很大差異。可能導致我們實際結果不同的因素或事件可能會不時出現,因此我們無法預測所有因素或事件。我們無法保證未來的結果、活動水平、表現或成就。公司沒有義務更新任何前瞻性陳述以反映本新聞稿發佈之日後可能發生的任何事件或情況。
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
Or 407-644-4256
STSS@redchip.com
投資者關係:
戴夫·金特里
RedChip 公司有限公司
1-800-RED-CHIP (733-2447)
或 407-644-4256
STSS@redchip.com
譯文內容由第三人軟體翻譯。